Drug watch. Pipeline progress: then and now.
The antiretroviral drug pipeline was last reviewed in BETA three years ago (see "The HIV/AIDS drug pipeline: a status report" in the Summer/Autumn 2002 issue). That report called on pharmaceutical companies to "ensure a steadier stream of innovative and affordable approaches to managing HIV infection." Is this goal being achieved?